June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Serratia marcescens Keratitis: Clinical Features, Risk Factors, Treatment, and Outcomes
Author Affiliations & Notes
  • Sarah Atta
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Chandrashan Perera
    Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, United States
  • Regis P Kowalski
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
    The Charles T. Campbell Ophthalmic Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
  • Vishal Jhanji
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Sarah Atta, None; Chandrashan Perera, None; Regis Kowalski, None; Vishal Jhanji, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1943. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sarah Atta, Chandrashan Perera, Regis P Kowalski, Vishal Jhanji; Serratia marcescens Keratitis: Clinical Features, Risk Factors, Treatment, and Outcomes. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1943.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To provide an up-to-date clinical characterization of Serratia marcescens keratitis and to assess changes in the microbiological spectrum and clinical trends of the infection over time.

Methods : Forty-six culture-proven cases (46 eyes) of Serratia marcescens ocular infection diagnosed and treated at the University of Pittsburgh Eye Center between Feb 2002-Feb 2020 were included in this retrospective, observational case series and reviewed for clinical and microbiological characteristics. Data collected from patient records included demographics, ocular and systemic risk factors, follow-up length, initial and final visual acuity, symptom duration prior to presentation, infiltrate size and shape, medical management, adjunctive management, time to defect closure, duration of treatment, microbiological characteristics, and antibiotic susceptibilities.

Results : Mean presenting age was 46.8 years with mean follow-up time of 329 days. Prevalent ocular comorbidities were contact lens use (68.6%), history of corneal disease (52.9%), lid pathology (25.5%), and glaucoma (15.7%). Systemic comorbidities were present in 58.8% of patients, with systemic atopy (49.0%) and immunosuppression (37.3%) being most common. Average treatment duration was 152 days, with most common administration of fluoroquinolones (76.5%) and fortified antibiotics (60.8%). Visual outcomes generally improved with treatment, with an average initial visual acuity (VA) of 1.3 logMar and final VA of 0.86 logMar. Worse final VA was associated with glaucoma (p=0.038), hypopyon (p=0.045), older age (0.000), worse initial VA (p=0.009), longer time to defect closure (p=0.020), and larger infiltrate (p=0.037). All cases showed antibiotic sensitivity to ciprofloxacin (100%), and most showed resistance to cefazolin (80.4%). No significant changes in clinical profile or treatment were observed over the 18-year period.

Conclusions : S. marcescens keratitis is associated with contact lens use and poor ocular surface. Fluoroquinolones and fortified antibiotics have shown effective management and improved visual outcomes. Worse outcomes are associated with older age and worse severity at presentation. Microbiological and clinical trends of this ocular infection have remained constant over nearly 20 years.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×